Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Freneslerbart/mevonlerbart - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Freneslerbart/mevonlerbart - Regeneron Pharmaceuticals

Alternative Names: REGN-1908-1909

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Allergy immunotherapies; Antiallergics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic conjunctivitis
  • Discontinued Allergic rhinitis; Hypersensitivity

Most Recent Events

  • 30 Jun 2026 Regeneron Pharmaceuticals plans a phase III clinical trial for Allergic conjunctivitis ( In children, In adolescents, In adults) in unknown location (SC) in July 2026 (NCT07675811)
  • 08 Sep 2025 Efficacy and adverse events data from a phase-III trial in allergic conjunctivitis released by Regeneron Pharmaceuticals
  • 28 May 2025 Regeneron Pharmaceuticals completes enrolment in its phase III clinical trials in Allergic conjunctivitis in USA and Canada (SC) (NCT06602726)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top